

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number [001-13467](#)

OMB APPROVAL

OMB Number:	3235-0080
Expires:	March 31, 2018
Estimated average burden hours per response:	1.7

Issuer: [COMMONWEALTH BIOTECHNOLOGIES INC](#)
Exchange: [NASDAQ Stock Market LLC](#)

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address: [601 Biotech Drive](#)
[Richmond VIRGINIA 23235](#)

Telephone number: [804-648-3820](#)

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

[Common Stock](#)

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

☐ 17 CFR 240.12d2-2(a)(1)

☐ 17 CFR 240.12d2-2(a)(2)

☐ 17 CFR 240.12d2-2(a)(3)

☐ 17 CFR 240.12d2-2(a)(4)

☒ Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. [1](#)

☐ Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements for the Securities Exchange Act of 1934, [NASDAQ Stock Market LLC](#) certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2010-04-09	By	Amy Horton	Associate General Counsel
Date		Name	Title

1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. [See](#) General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Delisting Determination, The Nasdaq Stock Market, LLC, April 9, 2010, Commonwealth Biotechnologies, Inc. The Nasdaq Stock Market, Inc. (the Exchange) has determined to remove from listing the common stock of Commonwealth Biotechnologies, Inc. (the Company), effective at the opening of the trading session on April 19, 2010. Based on review of information provided by the Company, Nasdaq Staff determined that the Company no longer qualified for listing on the Exchange pursuant to Listing Rules 5550(b)(1), 5110(a), and 5100. The Company was notified of the Staffs determination on July 24, 2009 and July 31, 2009. Upon review of the information provided by the Company, the Panel issued a decision dated October 20, 2009, granting the Company continued listing pursuant to an exception through January 20, 2010, by which date the Company was required to regain compliance with Listing Rules 5550(b)(1), 5110(a) and 5100. However, the Company did not regain compliance by that date. On January 21, 2010, the Panel notified the Company that trading in the Companys securities would be suspended on January 22, 2010. The Company did not request a review of the Panels decision by the Nasdaq Listing and Hearing Review Council. The Listing Council did not call the matter for review. The Panels Determination to delist the Company became final on March 8, 2010.